Xenoport, Inc.

Glaxo Group Limited

Mark A. Gallop

Suresh K. Manthati

Thu Phan

Maria Ludwikow

Stephen P. Raillard

Xuedong Dai

Fenmei Yao

Randall A. Scheuerman

Ge Peng

Seema Bhat

Stephen P Raillard

Suresh Kumar Manthati

Mark A Gallop

Randall A Scheuerman

Maria J Ludwikow

Seema Rani Bhat

Tono Estrada

Cindy X Zhou

Sudhir Joshi

Jia-Ning Xiang

Mark Quang Nguyen

Qunying Dai

Hao Yin

Uwe Zacher

Peng Liu

Christine Frauenfelder

Adam Mann

Methods of synthesizing a levodopa ester prodrug, salts thereof, and synthetic intermediates thereof are disclosed.

Methods of synthesizing a levodopa ester prodrug

Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof

Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

Method of making monomethyl fumarate

Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.

[object Object]

A crystalline form of a &#x3b3;-aminobutyric acid analog, and methods of preparing same, are provided.

Crystalline form of &#x3b3;-aminobutyric acid analog

Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.

The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods.

Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs

Methods of enzymatically resolving acyloxyalkyl thiocarbonates useful in the synthesis of acyloxyalkyl carbamate prodrugs are disclosed.

Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs

The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.

Growing community of inventors

Mountain View, CA, United States of America

Stephen P Raillard